PRODUCT DESCRIPTION
Oxford BioMedica’s 5T4 technology and intellectual property include monoclonal antibodies that bind to the 5T4 antigen. Wyeth is developing a targeted antibody therapy for the treatment of cancer using a humanised version of anti-5T4 antibody linked to a cytotoxic molecule, calicheamicin. The product is a ‘magic bullet’ approach, which is designed to deliver the conjugate directly and specifically to tumour cells, sparing healthy cells.

INDICATION
A wide range of cancers.

MARKET
The product could in principle be used to treat a wide range of cancers and could therefore command a substantial market.

TECHNICAL DESIGN
Humanised anti-5T4 antibody conjugated to a cytotoxic molecule, calicheamicin.

CLINICAL STATUS

• Wyeth is conducting further preclinical studies
• Preparations for clinical development are ongoing

PARTNERS/FUNDING
Wyeth

Website by College Hill - Life Sciences